"Diarylquinolines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of quinoline compounds defined by the presence of two aromatic ring structures which are attached via a side chain to carbon 3 of the qunolinyl structure. The two aromatic moieties are typically NAPTHALENE and BENZENE. Several compounds in this class are used as ANTITUBERCULAR AGENTS.
| Descriptor ID |
D064687
|
| MeSH Number(s) |
D03.633.100.810.087
|
| Concept/Terms |
Diarylquinolines- Diarylquinolines
- Diarylquinoline Derivatives
- Derivatives, Diarylquinoline
- Diaryl Quinoline Derivatives
- Derivatives, Diaryl Quinoline
- Quinoline Derivatives, Diaryl
|
Below are MeSH descriptors whose meaning is more general than "Diarylquinolines".
Below are MeSH descriptors whose meaning is more specific than "Diarylquinolines".
This graph shows the total number of publications written about "Diarylquinolines" by people in this website by year, and whether "Diarylquinolines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2015 | 1 | 0 | 1 |
| 2017 | 14 | 2 | 16 |
| 2018 | 13 | 6 | 19 |
| 2019 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Diarylquinolines" by people in Profiles.
-
Is PF-00835231 a Pan-SARS-CoV-2 Mpro Inhibitor? A Comparative Study. Molecules. 2021 Mar 17; 26(6).
-
Ligand and structure-based virtual screening applied to the SARS-CoV-2 main protease: an in silico repurposing study. Future Med Chem. 2020 10; 12(20):1815-1828.
-
Acquired Drug Resistance: Recognizing the Potential of Repurposed Drugs. Clin Infect Dis. 2019 11 13; 69(11):2038-2039.
-
BPaL approved for multidrug-resistant tuberculosis. Lancet Infect Dis. 2019 10; 19(10):1063-1064.
-
Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations. BMC Infect Dis. 2019 Sep 09; 19(1):794.
-
High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. Eur Respir J. 2018 12; 52(6).
-
Is 6 months of bedaquiline enough? Int J Tuberc Lung Dis. 2018 12 01; 22(12):1523-1524.
-
Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling. Antimicrob Agents Chemother. 2018 12; 62(12).
-
Clofazimine does not lead to significant QT interval prolongation: a multicentre study. Eur Respir J. 2018 11; 52(5).
-
Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China. Int J Infect Dis. 2019 Jan; 78:44-49.